Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

The U.S. Food and Drug Administration (FDA) has approved several label updates for CAR-T cell therapies marketed by Bristol ...

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value.

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Pharmaceutical company Novartis and the organization working to increase representation in advertising, the Cannes Can: ...

Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), ...

After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...